Lead Product(s): HT-001
Therapeutic Area: Dermatology Product Name: HT-001
Highest Development Status: Preclinical Product Type: Undisclosed
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 12, 2021
The finalization of the HT-001 formulation will allow the company to begin IND-enabling toxicology studies and manufacturing of clinical batches for the planned Phase 2a clinical trial.
Lead Product(s): MSB-3163
Therapeutic Area: Dermatology Product Name: MSB-3163
Highest Development Status: Preclinical Product Type: Large molecule
Partner/Sponsor/Collaborator: MatriSys Bioscience
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement March 18, 2021
MatriSys plans to quickly advance the development of MSB-3163 and conduct a first-in-human proof-of-concept clinical trial. MSB3163 exhibited potency greater than antibiotics commonly used in the treatment of acne in clinical trails.